Tag: oncolytic virus therapy market

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Oncolytic Virus Therapy Market CAGR Analysis And Future Market Development

The market for oncolytic virus therapies has experienced substantial expansion, projected to increase from $0.23 billion in 2025 to $0.29 billion in 2026, reflecting a compound annual growth rate of 23.7%. This upward trajectory during the preceding period was influenced by advancements in herpes simplex virus (HSV) and adenovirus-derived oncolytic treatments, initial research phases for melanoma and breast cancer, heightened engagement from cancer research bodies, augmented governmental financial backing for virotherapy investigation, and an increase in partnerships between biotechnology firms and educational establishments.

Anticipate a dramatic escalation in the oncolytic virus therapy market, projected to reach $0.68 billion by 2030, driven by a formidable CAGR of 23.7%. This surge is fueled by escalating requirements for genetically modified oncolytic viruses, broadening applications in treating lung, prostate, and brain cancers, the expansion of specialized clinics and hospitals providing virotherapy, increased investments in synergistic and novel virus treatments, and the development of clinical trial infrastructure in developing economies. Key developments expected during this period include the integration of artificial intelligence and big data into oncolytic virus research, greater utilization of genomics and personalized medicine for treatment strategies, enhanced deployment of digital platforms for overseeing clinical trials, increased automation in virus manufacturing and quality control processes, and the growing use of Internet of Things (IoT) technology for monitoring virus storage and delivery.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12391&type=smp

Oncolytic Virus Therapy Market Expansion Drivers: What Is Shaping Future Growth?

The expanding incidence of neoplastic diseases is anticipated to be a significant catalyst for the advancement of the oncolytic virus therapy sector in the future. Cancer, a broad classification of ailments defined by the aberrant proliferation and dissemination of atypical cells within an organism, presents a significant health challenge. Oncolytic virus treatments provide a promising avenue for selectively eradicating malignant cells and simultaneously mobilizing the body’s immune system to combat the tumor, thereby offering a multifaceted approach to cancer management. Illustratively, data released in February 2024 by the World Health Organization, an international body headquartered in Switzerland, forecast that by the year 2050, more than 35 million new cancer diagnoses would occur, an escalation of 77% from the approximately 20 million cases documented in 2022. Consequently, this escalating burden of cancer cases is directly fueling the expansion of the oncolytic virus therapy market.

Oncolytic Virus Therapy Market Segment Breakdown: Which Categories Generate The Most Revenue?

The oncolytic virus therapy market covered in this report is segmented –

1) By Therapy Type: Herpes Simplex Virus (HSV)-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, Newcastle Disease Virus (NDV), Other Therapy Types

2) By Virus Type: Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses

3) By Application: Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer

4) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes

Subsegments:

1) By Herpes Simplex Virus (HSV)-Based Oncolytic Virus Therapy: Genetically Modified Herpes Simplex Virus Oncolytic Viruses, T-VEC (Talimogene Laherparepvec) Therapy, Herpes Simplex Virus-Based Combination Therapies, Herpes Simplex Virus-Based Targeted Oncolytic Approaches

2) By Adenovirus-Based Oncolytic Virus Therapy: Conditionally Replicating Adenoviruses, Oncolytic Adenovirus Immunotherapies, Adenovirus-Based Combination Treatments, Targeted Adenovirus Therapies

3) By Reovirus: Reolysin Therapy, Genetically Engineered Reoviruses, Reovirus Combination Treatments, Tumor-Selective Reovirus Approaches

4) By Poxviruses: Vaccinia Virus-Based Oncolytic Therapies, Modified Vaccinia Ankara (MVA) Therapies, Poxvirus Combination Treatments, Tumor-Targeted Poxvirus Therapies

5) By Newcastle Disease Virus (NDV): Wild-Type Newcastle Disease Virus Therapies, Genetically Modified Newcastle Disease Virus Oncolytic Approaches, Newcastle Disease Virus Combination Therapies, Tumor-Selective Newcastle Disease Virus Treatments

6) By Other Therapy Types: Measles Virus-Based Oncolytic Therapies, Vesicular Stomatitis Virus (VSV) Therapies, Other Experimental Oncolytic Virus Treatments, Emerging Oncolytic Virus Platforms

Oncolytic Virus Therapy Market Strategic Trends: What Is Defining The Next Phase Of Growth?

Key players within the oncolytic virus therapy sector are prioritizing the acquisition of endorsements from regulatory bodies. This strategic focus aims to accelerate the market entry of novel treatment modalities for oncological conditions. Essentially, regulatory approvals signify the rigorous assessment and subsequent authorization procedures undertaken by health agencies to permit the commercial availability of medicinal products, encompassing pharmaceuticals, biological agents, and medical apparatus. Illustrating this, as recently as March 2024, ImmVira, a biotechnology firm headquartered in China, was granted Fast Track status by the FDA for its oncolytic virus therapeutic, MVR-T3011 IT. This treatment is slated for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) patients who have encountered disease advancement despite platinum-based chemotherapy and a preceding anti-PD-1/PD-L1 therapy regimen. Such expedited pathways are designated to streamline the development and evaluation timelines for treatments targeting significant ailments where existing medical requirements remain unfulfilled.

Oncolytic Virus Therapy Market Key Players And Strategic Industry Positioning

Major companies operating in the oncolytic virus therapy market are Sorrento Therapeutics Inc., Amgen Inc., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Provectus Biopharmaceuticals Inc., Vibalogics, Turnstone Biologics, PsiOxus Therapeutics Ltd., Targovax, Cold Genesys, Shanghai Sunway Biotech Co Ltd., Neotropix, Candel Therapeutics Inc., CG Oncology, DNAtrix Inc., Oryx GmbH, ViroCure, GeneMedicine, VCN Biosciences, Beijing Syngentech, KaliVir Immunotherapeutics Inc.

Access The Complete Oncolytic Virus Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

Oncolytic Virus Therapy Market Geographic Analysis: Where Is Demand Growing The Fastest?

North Americawas the largest region in the oncolytic virus therapy market in 2025 and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Larger Will The Oncolytic Virus Therapy Market Become By 2030 Compared To 2026?

The oncolytic virus therapy market has experienced significant expansion in recent years. Its valuation is projected to increase from $0.23 billion in 2025 to $0.29 billion in 2026, driven by a compound annual growth rate (CAGR) of 23.7%. This historical growth can be attributed to several contributing factors, such as the advancement of hsv- and adenovirus-based oncolytic therapies, early-stage clinical trials focused on melanoma and breast cancer, heightened interest from cancer research institutes, increased government funding allocated to virotherapy research, and a rise in collaborations between biotech companies and academic institutions.

The oncolytic virus therapy market is projected to experience substantial expansion in the coming years. This market is forecast to reach $0.68 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 23.7%. This anticipated growth is driven by several factors, including a heightened demand for genetically engineered oncolytic viruses, their increasing application in treating lung, prostate, and brain cancers, the proliferation of specialized clinics and hospitals providing virotherapy, greater investment in combined and novel virus therapies, and the expansion of clinical trial facilities within developing regions. Key developments expected during this period involve the growing integration of AI and big data into oncolytic virus research, enhanced utilization of genomics and precision medicine for designing therapies, broader deployment of digital platforms for overseeing clinical trials, increased automation in the manufacturing and quality control of viruses, and the expanding use of IoT-based systems for tracking virus storage and distribution.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12391&type=smp

Which Strategic Drivers Are Supporting The Oncolytic Virus Therapy Market Development?

The oncolytic virus therapy market is anticipated to expand due to the increasing prevalence of cancer cases. Cancer refers to a group of diseases marked by the uncontrolled multiplication and spread of abnormal cells throughout the body. Oncolytic virus therapy provides the ability to selectively target and destroy cancer cells while also stimulating an immune response against the tumor, offering a dual mechanism of action for effective cancer treatment. For instance, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected over 35 million new cancer cases by 2050, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the rising occurrence of cancer cases is driving the growth of the oncolytic virus therapy market.

Which Segment Divisions Form The Structure Of The Oncolytic Virus Therapy Market?

The oncolytic virus therapy market covered in this report is segmented –

1) By Therapy Type: Herpes Simplex Virus (HSV)-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, Newcastle Disease Virus (NDV), Other Therapy Types

2) By Virus Type: Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses

3) By Application: Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer

4) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes

Subsegments:

1) By Herpes Simplex Virus (HSV)-Based Oncolytic Virus Therapy: Genetically Modified Herpes Simplex Virus Oncolytic Viruses, T-VEC (Talimogene Laherparepvec) Therapy, Herpes Simplex Virus-Based Combination Therapies, Herpes Simplex Virus-Based Targeted Oncolytic Approaches

2) By Adenovirus-Based Oncolytic Virus Therapy: Conditionally Replicating Adenoviruses, Oncolytic Adenovirus Immunotherapies, Adenovirus-Based Combination Treatments, Targeted Adenovirus Therapies

3) By Reovirus: Reolysin Therapy, Genetically Engineered Reoviruses, Reovirus Combination Treatments, Tumor-Selective Reovirus Approaches

4) By Poxviruses: Vaccinia Virus-Based Oncolytic Therapies, Modified Vaccinia Ankara (MVA) Therapies, Poxvirus Combination Treatments, Tumor-Targeted Poxvirus Therapies

5) By Newcastle Disease Virus (NDV): Wild-Type Newcastle Disease Virus Therapies, Genetically Modified Newcastle Disease Virus Oncolytic Approaches, Newcastle Disease Virus Combination Therapies, Tumor-Selective Newcastle Disease Virus Treatments

6) By Other Therapy Types: Measles Virus-Based Oncolytic Therapies, Vesicular Stomatitis Virus (VSV) Therapies, Other Experimental Oncolytic Virus Treatments, Emerging Oncolytic Virus Platforms

What Trends Are Driving Changes In The Oncolytic Virus Therapy Market?

Leading firms within the oncolytic adenovirus market are prioritizing combination treatments like VCN-01, a strategy that merges oncolytic virotherapy with chemotherapy to boost tumor targeting and elevate therapeutic results. This VCN-01 is an oncolytic adenovirus specifically designed to infect and eradicate cancer cells, simultaneously amplifying the efficacy of chemotherapy. As an illustration, in May 2024, Theriva Biologics, a US-based clinical-stage immuno-oncology firm, disclosed that the U.S. Food and Drug Administration (FDA) awarded Fast Track Designation (FTD) to its primary candidate, VCN-01. The designation specifically applies to VCN-01 when administered alongside gemcitabine and nab-paclitaxel to treat metastatic pancreatic adenocarcinoma. VCN-01 functions as an oncolytic adenovirus by targeting and reproducing within tumor cells, thereby aiding in the degradation of the tumor stroma, which represents a significant barrier to successful cancer therapy.

Which Companies Are Engaged In The Oncolytic Virus Therapy Market Environment?

Major companies operating in the oncolytic virus therapy market are Sorrento Therapeutics Inc., Amgen Inc., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Provectus Biopharmaceuticals Inc., Vibalogics, Turnstone Biologics, PsiOxus Therapeutics Ltd., Targovax, Cold Genesys, Shanghai Sunway Biotech Co Ltd., Neotropix, Candel Therapeutics Inc., CG Oncology, DNAtrix Inc., Oryx GmbH, ViroCure, GeneMedicine, VCN Biosciences, Beijing Syngentech, KaliVir Immunotherapeutics Inc.

Access The Complete Oncolytic Virus Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

Which Region Stands As The Largest Contributor To The Oncolytic Virus Therapy Market?

North America was the largest region in the oncolytic virus therapy market in 2025 and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Oncolytic Virus Therapy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=12391&type=smp

Browse Through More Reports Similar to the Global Oncolytic Virus Therapy Market 2026, By The Business Research Company

Clinical Nutrition For Cancer Care Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-nutrition-for-cancer-care-global-market-report

Oncology Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Oncology Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Market Size Trajectory Of The Oncolytic Virus Therapy Market From 2026 To 2030?

The oncolytic virus therapy market has experienced substantial expansion in recent years. Its value is projected to increase from $0.23 billion in 2025 to $0.29 billion in 2026, achieving a compound annual growth rate (CAGR) of 23.7%. The growth observed in the preceding period can be attributed to various factors, including the development of hsv- and adenovirus-based oncolytic therapies, early clinical trials targeting melanoma and breast cancer, increasing interest from cancer research institutes, rising government funding for virotherapy research, and an increase in collaborations between biotech companies and academic institutions.

The oncolytic virus therapy market is poised for significant expansion in the coming years. This market is projected to reach $0.68 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 23.7%. This anticipated growth during the forecast period is fueled by several factors, including an escalating demand for genetically engineered oncolytic viruses, their increasing application in treating lung, prostate, and brain cancers, the proliferation of specialized clinics and hospitals providing virotherapy, increased investments in developing combination and novel virus therapies, and the expansion of clinical trial facilities in developing regions. Key trends anticipated during this period encompass the growing integration of AI and big data in oncolytic virus research, enhanced utilization of genomics and precision medicine for designing therapies, wider adoption of digital platforms for overseeing clinical trials, increased automation in the production and quality assurance of viruses, and the expanding deployment of IoT-based systems for monitoring virus storage and distribution.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12391&type=smp

Which Primary Drivers Are Impacting The Oncolytic Virus Therapy Market Growth?

The oncolytic virus therapy market is anticipated to expand due to the rising occurrence of cancer cases. Cancer refers to a collection of illnesses defined by the uncontrolled proliferation and dissemination of atypical cells throughout the body. Oncolytic virus therapy provides a means to specifically identify and eliminate cancer cells, concurrently activating an immune reaction against the tumor, thereby offering a two-pronged approach for successful cancer treatment. As an example, the World Health Organization, an intergovernmental body based in Switzerland, reported in February 2024 that more than 35 million new cancer cases are forecast by 2050, marking a 77% rise from the approximately 20 million cases estimated in 2022. Consequently, the growing incidence of cancer cases is fueling the expansion of the oncolytic virus therapy market.

What Are The Key Segment Divisions In The Oncolytic Virus Therapy Market Segment Structure?

The oncolytic virus therapy market covered in this report is segmented –

1) By Therapy Type: Herpes Simplex Virus (HSV)-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, Newcastle Disease Virus (NDV), Other Therapy Types

2) By Virus Type: Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses

3) By Application: Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer

4) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes

Subsegments:

1) By Herpes Simplex Virus (HSV)-Based Oncolytic Virus Therapy: Genetically Modified Herpes Simplex Virus Oncolytic Viruses, T-VEC (Talimogene Laherparepvec) Therapy, Herpes Simplex Virus-Based Combination Therapies, Herpes Simplex Virus-Based Targeted Oncolytic Approaches

2) By Adenovirus-Based Oncolytic Virus Therapy: Conditionally Replicating Adenoviruses, Oncolytic Adenovirus Immunotherapies, Adenovirus-Based Combination Treatments, Targeted Adenovirus Therapies

3) By Reovirus: Reolysin Therapy, Genetically Engineered Reoviruses, Reovirus Combination Treatments, Tumor-Selective Reovirus Approaches

4) By Poxviruses: Vaccinia Virus-Based Oncolytic Therapies, Modified Vaccinia Ankara (MVA) Therapies, Poxvirus Combination Treatments, Tumor-Targeted Poxvirus Therapies

5) By Newcastle Disease Virus (NDV): Wild-Type Newcastle Disease Virus Therapies, Genetically Modified Newcastle Disease Virus Oncolytic Approaches, Newcastle Disease Virus Combination Therapies, Tumor-Selective Newcastle Disease Virus Treatments

6) By Other Therapy Types: Measles Virus-Based Oncolytic Therapies, Vesicular Stomatitis Virus (VSV) Therapies, Other Experimental Oncolytic Virus Treatments, Emerging Oncolytic Virus Platforms

Which Trends Are Shaping Growth In The Oncolytic Virus Therapy Market?

Leading companies in the oncolytic virus therapy market are prioritizing the attainment of regulatory approvals to accelerate the introduction of novel therapies for cancer treatment. Regulatory approvals signify the process by which health authorities evaluate and authorize medical products, including drugs, biologics, and medical devices, for market use. For example, in March 2024, ImmVira, a biotechnology company based in China, secured Fast Track designation from the FDA for its oncolytic virus therapy, MVR-T3011 IT. This therapy is intended for the treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients who have shown disease progression after platinum-based chemotherapy and at least one previous line of anti-PD-1/PD-L1 therapy. This designation aims to expedite the development and review pathways for therapies addressing serious conditions with unfulfilled medical requirements.

Which Organizations Are Engaged In The Oncolytic Virus Therapy Market?

Major companies operating in the oncolytic virus therapy market are Sorrento Therapeutics Inc., Amgen Inc., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Provectus Biopharmaceuticals Inc., Vibalogics, Turnstone Biologics, PsiOxus Therapeutics Ltd., Targovax, Cold Genesys, Shanghai Sunway Biotech Co Ltd., Neotropix, Candel Therapeutics Inc., CG Oncology, DNAtrix Inc., Oryx GmbH, ViroCure, GeneMedicine, VCN Biosciences, Beijing Syngentech, KaliVir Immunotherapeutics Inc.

Get The Full Oncolytic Virus Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

Which Region Is The Largest In The Oncolytic Virus Therapy Market?

North America was the largest region in the oncolytic virus therapy market in 2025 and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Oncolytic Virus Therapy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

Browse Through More Reports Similar to the Global Oncolytic Virus Therapy Market 2026, By The Business Research Company

Clinical Nutrition For Cancer Care Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-nutrition-for-cancer-care-global-market-report

Oncology Drugs Market

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Oncology Drugs Market

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Oncolytic Virus Therapy Market During 2026–2030?

The oncolytic virus therapy market has experienced significant expansion in recent years. Its valuation is predicted to increase from $0.23 billion in 2025 to $0.29 billion in 2026, achieving a compound annual growth rate (CAGR) of 23.7%. This historical progression can be attributed to several factors: the creation of HSV- and adenovirus-based oncolytic treatments, early clinical trials targeting melanoma and breast cancer, a surge in interest from cancer research institutes, augmented government funding for virotherapy research, and strengthening collaborations between biotechnology firms and academic institutions.

The oncolytic virus therapy market is projected to experience substantial growth over the next few years. It is anticipated to expand to $0.68 billion by 2030, achieving a compound annual growth rate (CAGR) of 23.7%. This growth during the forecast period is attributable to an escalating demand for genetically engineered oncolytic viruses, their increasing adoption in lung, prostate, and brain cancers, the expansion of specialty clinics and hospitals offering virotherapy, rising investment in combination and emerging virus therapies, and the development of clinical trial infrastructure in nascent markets. Major trends expected in the forecast period include the increasing integration of AI and big data into oncolytic virus research, a greater focus on genomics and precision medicine for therapy design, broader implementation of digital platforms for clinical trial monitoring, enhanced automation in virus production and quality assurance, and the expanding use of IoT-based systems for monitoring virus storage and distribution.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12391&type=smp

Which Economic Or Industry Drivers Are Impacting The Oncolytic Virus Therapy Market?

The rising occurrence of cancer cases is anticipated to propel the expansion of the oncolytic virus therapy market moving forward. Cancer describes a collection of diseases defined by the uncontrolled proliferation and spread of abnormal cells within the body. Oncolytic virus therapy provides the ability to selectively target and eliminate cancer cells, while also stimulating an immune response against the tumor, thereby offering a dual mechanism of action for effective cancer treatment. For instance, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected over 35 million new cancer cases by 2050, which represents a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the rising prevalence of cancer cases is a key factor driving the growth of the oncolytic virus therapy market.

How Are The Various Segments Of The Oncolytic Virus Therapy Market Categorized?

The oncolytic virus therapy market covered in this report is segmented –

1) By Therapy Type: Herpes Simplex Virus (HSV)-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, Newcastle Disease Virus (NDV), Other Therapy Types

2) By Virus Type: Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses

3) By Application: Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer

4) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes

Subsegments:

1) By Herpes Simplex Virus (HSV)-Based Oncolytic Virus Therapy: Genetically Modified Herpes Simplex Virus Oncolytic Viruses, T-VEC (Talimogene Laherparepvec) Therapy, Herpes Simplex Virus-Based Combination Therapies, Herpes Simplex Virus-Based Targeted Oncolytic Approaches

2) By Adenovirus-Based Oncolytic Virus Therapy: Conditionally Replicating Adenoviruses, Oncolytic Adenovirus Immunotherapies, Adenovirus-Based Combination Treatments, Targeted Adenovirus Therapies

3) By Reovirus: Reolysin Therapy, Genetically Engineered Reoviruses, Reovirus Combination Treatments, Tumor-Selective Reovirus Approaches

4) By Poxviruses: Vaccinia Virus-Based Oncolytic Therapies, Modified Vaccinia Ankara (MVA) Therapies, Poxvirus Combination Treatments, Tumor-Targeted Poxvirus Therapies

5) By Newcastle Disease Virus (NDV): Wild-Type Newcastle Disease Virus Therapies, Genetically Modified Newcastle Disease Virus Oncolytic Approaches, Newcastle Disease Virus Combination Therapies, Tumor-Selective Newcastle Disease Virus Treatments

6) By Other Therapy Types: Measles Virus-Based Oncolytic Therapies, Vesicular Stomatitis Virus (VSV) Therapies, Other Experimental Oncolytic Virus Treatments, Emerging Oncolytic Virus Platforms

What Trends Are Advancing Progress In The Oncolytic Virus Therapy Market?

Major companies operating in the oncolytic virus therapy market are primarily focused on obtaining regulatory approvals to accelerate the introduction of innovative therapies for cancer treatment. Regulatory approvals signify the process through which health authorities evaluate and authorize medical products, including drugs, biologics, and medical devices, for market use. For instance, in March 2024, ImmVira, a China-based biotechnology company, was granted Fast Track designation by the FDA for its oncolytic virus therapy, MVR-T3011 IT, intended for treating recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients who have experienced disease progression after platinum-based chemotherapy and at least one prior line of anti-PD-1/PD-L1 therapy. This designation is designed to expedite the development and review process for therapies addressing serious conditions with unmet medical needs.

Which Major Firms Influence Developments In The Oncolytic Virus Therapy Market?

Major companies operating in the oncolytic virus therapy market are Sorrento Therapeutics Inc., Amgen Inc., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Provectus Biopharmaceuticals Inc., Vibalogics, Turnstone Biologics, PsiOxus Therapeutics Ltd., Targovax, Cold Genesys, Shanghai Sunway Biotech Co Ltd., Neotropix, Candel Therapeutics Inc., CG Oncology, DNAtrix Inc., Oryx GmbH, ViroCure, GeneMedicine, VCN Biosciences, Beijing Syngentech, KaliVir Immunotherapeutics Inc.

Read the full oncolytic virus therapy market report here:

https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

What Are The Top-Performing Regions Within The Oncolytic Virus Therapy Market?

North America was the largest region in the oncolytic virus therapy market in 2025 and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Oncolytic Virus Therapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12391&type=smp

Browse Through More Reports Similar to the Global Oncolytic Virus Therapy Market 2026, By The Business Research Company

Clinical Nutrition For Cancer Care Global Market Report

https://www.thebusinessresearchcompany.com/report/clinical-nutrition-for-cancer-care-global-market-report

Oncology Drugs Market

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Oncology Drugs Market

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Oncolytic Virus Therapy Market During 2026–2030?

The oncolytic virus therapy market has experienced significant expansion in recent years. Its valuation is predicted to increase from $0.23 billion in 2025 to $0.29 billion in 2026, achieving a compound annual growth rate (CAGR) of 23.7%. This historical progression can be attributed to several factors: the creation of HSV- and adenovirus-based oncolytic treatments, early clinical trials targeting melanoma and breast cancer, a surge in interest from cancer research institutes, augmented government funding for virotherapy research, and strengthening collaborations between biotechnology firms and academic institutions.

The oncolytic virus therapy market is projected to experience substantial growth over the next few years. It is anticipated to expand to $0.68 billion by 2030, achieving a compound annual growth rate (CAGR) of 23.7%. This growth during the forecast period is attributable to an escalating demand for genetically engineered oncolytic viruses, their increasing adoption in lung, prostate, and brain cancers, the expansion of specialty clinics and hospitals offering virotherapy, rising investment in combination and emerging virus therapies, and the development of clinical trial infrastructure in nascent markets. Major trends expected in the forecast period include the increasing integration of AI and big data into oncolytic virus research, a greater focus on genomics and precision medicine for therapy design, broader implementation of digital platforms for clinical trial monitoring, enhanced automation in virus production and quality assurance, and the expanding use of IoT-based systems for monitoring virus storage and distribution.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12391&type=smp

Which Economic Or Industry Drivers Are Impacting The Oncolytic Virus Therapy Market?

The rising occurrence of cancer cases is anticipated to propel the expansion of the oncolytic virus therapy market moving forward. Cancer describes a collection of diseases defined by the uncontrolled proliferation and spread of abnormal cells within the body. Oncolytic virus therapy provides the ability to selectively target and eliminate cancer cells, while also stimulating an immune response against the tumor, thereby offering a dual mechanism of action for effective cancer treatment. For instance, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected over 35 million new cancer cases by 2050, which represents a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the rising prevalence of cancer cases is a key factor driving the growth of the oncolytic virus therapy market.

How Are The Various Segments Of The Oncolytic Virus Therapy Market Categorized?

The oncolytic virus therapy market covered in this report is segmented –

1) By Therapy Type: Herpes Simplex Virus (HSV)-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, Newcastle Disease Virus (NDV), Other Therapy Types

2) By Virus Type: Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses

3) By Application: Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer

4) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes

Subsegments:

1) By Herpes Simplex Virus (HSV)-Based Oncolytic Virus Therapy: Genetically Modified Herpes Simplex Virus Oncolytic Viruses, T-VEC (Talimogene Laherparepvec) Therapy, Herpes Simplex Virus-Based Combination Therapies, Herpes Simplex Virus-Based Targeted Oncolytic Approaches

2) By Adenovirus-Based Oncolytic Virus Therapy: Conditionally Replicating Adenoviruses, Oncolytic Adenovirus Immunotherapies, Adenovirus-Based Combination Treatments, Targeted Adenovirus Therapies

3) By Reovirus: Reolysin Therapy, Genetically Engineered Reoviruses, Reovirus Combination Treatments, Tumor-Selective Reovirus Approaches

4) By Poxviruses: Vaccinia Virus-Based Oncolytic Therapies, Modified Vaccinia Ankara (MVA) Therapies, Poxvirus Combination Treatments, Tumor-Targeted Poxvirus Therapies

5) By Newcastle Disease Virus (NDV): Wild-Type Newcastle Disease Virus Therapies, Genetically Modified Newcastle Disease Virus Oncolytic Approaches, Newcastle Disease Virus Combination Therapies, Tumor-Selective Newcastle Disease Virus Treatments

6) By Other Therapy Types: Measles Virus-Based Oncolytic Therapies, Vesicular Stomatitis Virus (VSV) Therapies, Other Experimental Oncolytic Virus Treatments, Emerging Oncolytic Virus Platforms

What Trends Are Advancing Progress In The Oncolytic Virus Therapy Market?

Major companies operating in the oncolytic virus therapy market are primarily focused on obtaining regulatory approvals to accelerate the introduction of innovative therapies for cancer treatment. Regulatory approvals signify the process through which health authorities evaluate and authorize medical products, including drugs, biologics, and medical devices, for market use. For instance, in March 2024, ImmVira, a China-based biotechnology company, was granted Fast Track designation by the FDA for its oncolytic virus therapy, MVR-T3011 IT, intended for treating recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients who have experienced disease progression after platinum-based chemotherapy and at least one prior line of anti-PD-1/PD-L1 therapy. This designation is designed to expedite the development and review process for therapies addressing serious conditions with unmet medical needs.

Which Major Firms Influence Developments In The Oncolytic Virus Therapy Market?

Major companies operating in the oncolytic virus therapy market are Sorrento Therapeutics Inc., Amgen Inc., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Provectus Biopharmaceuticals Inc., Vibalogics, Turnstone Biologics, PsiOxus Therapeutics Ltd., Targovax, Cold Genesys, Shanghai Sunway Biotech Co Ltd., Neotropix, Candel Therapeutics Inc., CG Oncology, DNAtrix Inc., Oryx GmbH, ViroCure, GeneMedicine, VCN Biosciences, Beijing Syngentech, KaliVir Immunotherapeutics Inc.

Read the full oncolytic virus therapy market report here:

https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

What Are The Top-Performing Regions Within The Oncolytic Virus Therapy Market?

North America was the largest region in the oncolytic virus therapy market in 2025 and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Oncolytic Virus Therapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12391&type=smp

Browse Through More Reports Similar to the Global Oncolytic Virus Therapy Market 2026, By The Business Research Company

Clinical Nutrition For Cancer Care Global Market Report

https://www.thebusinessresearchcompany.com/report/clinical-nutrition-for-cancer-care-global-market-report

Oncology Drugs Market

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Oncology Drugs Market

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Oncolytic Virus Therapy Market During 2026–2030?

The oncolytic virus therapy market has experienced significant expansion in recent years. Its valuation is predicted to increase from $0.23 billion in 2025 to $0.29 billion in 2026, achieving a compound annual growth rate (CAGR) of 23.7%. This historical progression can be attributed to several factors: the creation of HSV- and adenovirus-based oncolytic treatments, early clinical trials targeting melanoma and breast cancer, a surge in interest from cancer research institutes, augmented government funding for virotherapy research, and strengthening collaborations between biotechnology firms and academic institutions.

The oncolytic virus therapy market is projected to experience substantial growth over the next few years. It is anticipated to expand to $0.68 billion by 2030, achieving a compound annual growth rate (CAGR) of 23.7%. This growth during the forecast period is attributable to an escalating demand for genetically engineered oncolytic viruses, their increasing adoption in lung, prostate, and brain cancers, the expansion of specialty clinics and hospitals offering virotherapy, rising investment in combination and emerging virus therapies, and the development of clinical trial infrastructure in nascent markets. Major trends expected in the forecast period include the increasing integration of AI and big data into oncolytic virus research, a greater focus on genomics and precision medicine for therapy design, broader implementation of digital platforms for clinical trial monitoring, enhanced automation in virus production and quality assurance, and the expanding use of IoT-based systems for monitoring virus storage and distribution.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12391&type=smp

Which Economic Or Industry Drivers Are Impacting The Oncolytic Virus Therapy Market?

The rising occurrence of cancer cases is anticipated to propel the expansion of the oncolytic virus therapy market moving forward. Cancer describes a collection of diseases defined by the uncontrolled proliferation and spread of abnormal cells within the body. Oncolytic virus therapy provides the ability to selectively target and eliminate cancer cells, while also stimulating an immune response against the tumor, thereby offering a dual mechanism of action for effective cancer treatment. For instance, in February 2024, the World Health Organization, a Switzerland-based intergovernmental organization, projected over 35 million new cancer cases by 2050, which represents a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the rising prevalence of cancer cases is a key factor driving the growth of the oncolytic virus therapy market.

How Are The Various Segments Of The Oncolytic Virus Therapy Market Categorized?

The oncolytic virus therapy market covered in this report is segmented –

1) By Therapy Type: Herpes Simplex Virus (HSV)-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, Newcastle Disease Virus (NDV), Other Therapy Types

2) By Virus Type: Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses

3) By Application: Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer

4) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes

Subsegments:

1) By Herpes Simplex Virus (HSV)-Based Oncolytic Virus Therapy: Genetically Modified Herpes Simplex Virus Oncolytic Viruses, T-VEC (Talimogene Laherparepvec) Therapy, Herpes Simplex Virus-Based Combination Therapies, Herpes Simplex Virus-Based Targeted Oncolytic Approaches

2) By Adenovirus-Based Oncolytic Virus Therapy: Conditionally Replicating Adenoviruses, Oncolytic Adenovirus Immunotherapies, Adenovirus-Based Combination Treatments, Targeted Adenovirus Therapies

3) By Reovirus: Reolysin Therapy, Genetically Engineered Reoviruses, Reovirus Combination Treatments, Tumor-Selective Reovirus Approaches

4) By Poxviruses: Vaccinia Virus-Based Oncolytic Therapies, Modified Vaccinia Ankara (MVA) Therapies, Poxvirus Combination Treatments, Tumor-Targeted Poxvirus Therapies

5) By Newcastle Disease Virus (NDV): Wild-Type Newcastle Disease Virus Therapies, Genetically Modified Newcastle Disease Virus Oncolytic Approaches, Newcastle Disease Virus Combination Therapies, Tumor-Selective Newcastle Disease Virus Treatments

6) By Other Therapy Types: Measles Virus-Based Oncolytic Therapies, Vesicular Stomatitis Virus (VSV) Therapies, Other Experimental Oncolytic Virus Treatments, Emerging Oncolytic Virus Platforms

What Trends Are Advancing Progress In The Oncolytic Virus Therapy Market?

Major companies operating in the oncolytic virus therapy market are primarily focused on obtaining regulatory approvals to accelerate the introduction of innovative therapies for cancer treatment. Regulatory approvals signify the process through which health authorities evaluate and authorize medical products, including drugs, biologics, and medical devices, for market use. For instance, in March 2024, ImmVira, a China-based biotechnology company, was granted Fast Track designation by the FDA for its oncolytic virus therapy, MVR-T3011 IT, intended for treating recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients who have experienced disease progression after platinum-based chemotherapy and at least one prior line of anti-PD-1/PD-L1 therapy. This designation is designed to expedite the development and review process for therapies addressing serious conditions with unmet medical needs.

Which Major Firms Influence Developments In The Oncolytic Virus Therapy Market?

Major companies operating in the oncolytic virus therapy market are Sorrento Therapeutics Inc., Amgen Inc., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Provectus Biopharmaceuticals Inc., Vibalogics, Turnstone Biologics, PsiOxus Therapeutics Ltd., Targovax, Cold Genesys, Shanghai Sunway Biotech Co Ltd., Neotropix, Candel Therapeutics Inc., CG Oncology, DNAtrix Inc., Oryx GmbH, ViroCure, GeneMedicine, VCN Biosciences, Beijing Syngentech, KaliVir Immunotherapeutics Inc.

Read the full oncolytic virus therapy market report here:

https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

What Are The Top-Performing Regions Within The Oncolytic Virus Therapy Market?

North America was the largest region in the oncolytic virus therapy market in 2025 and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Oncolytic Virus Therapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12391&type=smp

Browse Through More Reports Similar to the Global Oncolytic Virus Therapy Market 2026, By The Business Research Company

Clinical Nutrition For Cancer Care Global Market Report

https://www.thebusinessresearchcompany.com/report/clinical-nutrition-for-cancer-care-global-market-report

Oncology Drugs Market

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Oncology Drugs Market

https://www.thebusinessresearchcompany.com/report/oncology-drugs-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the oncolytic virus therapy market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Oncolytic Virus Therapy Market?

The oncolytic virus therapy market has experienced substantial expansion in recent years. This market is projected to grow from $0.23 billion in 2025 to $0.29 billion in 2026, achieving a compound annual growth rate (CAGR) of 23.7%. The historical increase can be attributed to factors such as the development of hsv- and adenovirus-based oncolytic therapies, the execution of early clinical trials for melanoma and breast cancer, a rising interest from cancer research institutes, increasing government funding for virotherapy research, and a growth in collaborations between biotech companies and academic institutions.

The oncolytic virus therapy market is projected to experience substantial expansion over the coming years, reaching a valuation of $0.68 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 23.7%. This anticipated growth during the forecast period is driven by several factors, including an escalating demand for genetically engineered oncolytic viruses, their increasing application in treating lung, prostate, and brain cancers, the proliferation of specialized clinics and hospitals providing virotherapy, growing investment in combination and novel virus therapies, and the expansion of clinical trial infrastructure within developing markets. Key trends expected during this period encompass the growing integration of AI and big data in oncolytic virus research, enhanced utilization of genomics and precision medicine for designing therapies, broader deployment of digital platforms for overseeing clinical trials, increased automation in virus manufacturing and quality control, and the expansion of IoT-based systems for monitoring virus storage and distribution.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12391&type=smp

Which Drivers Are Supporting The Rise Of The Oncolytic Virus Therapy Market?

The growing occurrence of cancer cases is anticipated to drive the expansion of the oncolytic virus therapy market in the future. Cancer refers to a collection of illnesses marked by the uncontrolled multiplication and dispersion of atypical cells within the body. Oncolytic virus therapy has the capability to selectively attack and eliminate cancer cells, simultaneously boosting an immune reaction against the tumor, thus offering a two-pronged approach for successful cancer treatment. For example, in February 2024, the World Health Organization, an intergovernmental body based in Switzerland, reported a projection of over 35 million new cancer cases by 2050. This signifies a 77% rise from the estimated 20 million cases recorded in 2022. Consequently, the rising incidence of cancer cases is fueling the growth of the oncolytic virus therapy market.

What Segments Are Identified Within The Structure Of The Oncolytic Virus Therapy Market?

The oncolytic virus therapy market covered in this report is segmented –

1) By Therapy Type: Herpes Simplex Virus (HSV)-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, Newcastle Disease Virus (NDV), Other Therapy Types

2) By Virus Type: Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses

3) By Application: Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer

4) By End-User: Hospitals, Specialty Clinics, Cancer Research Institutes

Subsegments:

1) By Herpes Simplex Virus (HSV)-Based Oncolytic Virus Therapy: Genetically Modified Herpes Simplex Virus Oncolytic Viruses, T-VEC (Talimogene Laherparepvec) Therapy, Herpes Simplex Virus-Based Combination Therapies, Herpes Simplex Virus-Based Targeted Oncolytic Approaches

2) By Adenovirus-Based Oncolytic Virus Therapy: Conditionally Replicating Adenoviruses, Oncolytic Adenovirus Immunotherapies, Adenovirus-Based Combination Treatments, Targeted Adenovirus Therapies

3) By Reovirus: Reolysin Therapy, Genetically Engineered Reoviruses, Reovirus Combination Treatments, Tumor-Selective Reovirus Approaches

4) By Poxviruses: Vaccinia Virus-Based Oncolytic Therapies, Modified Vaccinia Ankara (MVA) Therapies, Poxvirus Combination Treatments, Tumor-Targeted Poxvirus Therapies

5) By Newcastle Disease Virus (NDV): Wild-Type Newcastle Disease Virus Therapies, Genetically Modified Newcastle Disease Virus Oncolytic Approaches, Newcastle Disease Virus Combination Therapies, Tumor-Selective Newcastle Disease Virus Treatments

6) By Other Therapy Types: Measles Virus-Based Oncolytic Therapies, Vesicular Stomatitis Virus (VSV) Therapies, Other Experimental Oncolytic Virus Treatments, Emerging Oncolytic Virus Platforms

What Trends Are Expected To Impact The Competitive Landscape Of The Oncolytic Virus Therapy Market?

Key companies operating within the oncolytic virus therapy market are primarily focused on acquiring regulatory approvals to hasten the launch of new cancer treatment solutions. Regulatory approvals denote the formal procedure through which health authorities assess and sanction medical products, encompassing drugs, biologics, and medical devices, for commercial availability. For instance, in March 2024, ImmVira, a China-based biotechnology firm, was granted Fast Track designation by the FDA for MVR-T3011 IT, its oncolytic virus therapy. This therapy targets recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in patients who have shown disease progression subsequent to platinum-based chemotherapy and at least one previous line of anti-PD-1/PD-L1 therapy. Such a designation is designed to accelerate the development and review of therapies intended for serious conditions with existing unmet medical needs.

Which Key Players Are Driving Competition In The Oncolytic Virus Therapy Market?

Major companies operating in the oncolytic virus therapy market are Sorrento Therapeutics Inc., Amgen Inc., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Provectus Biopharmaceuticals Inc., Vibalogics, Turnstone Biologics, PsiOxus Therapeutics Ltd., Targovax, Cold Genesys, Shanghai Sunway Biotech Co Ltd., Neotropix, Candel Therapeutics Inc., CG Oncology, DNAtrix Inc., Oryx GmbH, ViroCure, GeneMedicine, VCN Biosciences, Beijing Syngentech, KaliVir Immunotherapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report

Which Region Currently Holds The Largest Share Of The Oncolytic Virus Therapy Market?

North America was the largest region in the oncolytic virus therapy market in 2025 and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Oncolytic Virus Therapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12391&type=smp

Browse Through More Reports Similar to the Global Oncolytic Virus Therapy Market 2026, By The Business Research Company

Infectious Disease Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/infectious-disease-therapeutics-global-market-report

Antiviral Combination Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Antivirals Market Report 2026

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model